CAR T cells in autoimmunity: game changer or stepping stone?

Area of Science:

• Immunology
• Cell Therapy
• Autoimmune Diseases

Background:

• Chimeric antigen receptor (CAR) T cells have transformed hematologic malignancy treatment.
• Emerging data suggest CAR T-cell therapy efficacy in autoimmune diseases (AIDs).

Purpose of the Study:

• Evaluate early successes of B-cell-targeting CAR T-cell therapy in AIDs.
• Discuss future implications, challenges, and advancements in CAR T-cell therapy for AIDs.

Main Methods:

• Review of early clinical applications of CAR T-cells in AIDs, focusing on systemic lupus erythematosus.
• Analysis of immune system changes and therapeutic advantages.
• Exploration of technological advances and alternative therapies like bispecific antibodies.

Main Results:

• Significant and durable clinical remissions observed in refractory AIDs, particularly systemic lupus erythematosus.
• Evidence of immune system 'reset' with reduced innate inflammation and adaptive autoimmunity.
• CAR T cells demonstrate deep B-cell depletion and activity in inflamed tissues.

Conclusions:

• CAR T-cell therapy holds transformative potential for AIDs, offering unique therapeutic benefits.
• Key challenges include long-term toxicity, secondary malignancy risk, and accessibility.
• Ongoing research into next-generation CAR T cells, allogeneic products, and bispecific antibodies aims to improve safety and efficacy.